Introduction: Diagnosis of infections due to Mycobacterium tuberculosis has been recently facilitated with the worldwide implementation of rapid molecular tests. However, the diagnosis of non-TB mycobacteria (NTM) remains a major challenge for laboratories, as this group of bacteria contains over 150 different species with highly variable bacteriological properties. The development and implementation in clinical practice of techniques allowing rapid identification of NTM at the species level is, therefore, important for clinical laboratories. We report the case of an HIV-1 positive patient presenting with severe NTM infection who benefited from a novel rapid diagnostic technique, based on the direct sequencing of the rpoB gene from smear-positive clinical samples.
Introduction
The diagnosis of infections due to Mycobacterium tuberculosis (Mtb) has made an unprecedented step forward recently with the worldwide implementation of rapid molecular tests. However, the diagnosis of non-TB mycobacteria (NTM) remains a major challenge for laboratories, as this group of bacteria contains over 150 different species presenting with variable bacteriological properties and clinical significance. Current molecular techniques lack sensitivity and are unable to distinguish mycobacterial species or subspecies to a level that would guide therapeutic management. Development of techniques allowing rapid identification of NTM at the species level is, therefore, important for clinical laboratories. †These authors contributed equally to this paper.
Abbreviations: ART, antiretroviral therapy; FDG PET CT, fluorodeoxyglucose positron emission tomography computed tomography; HIV, human immunodeficiency virus; IRIS, immune reconstitution inflammatory syndrome; Mtb, Mycobacterium tuberculosis; NTM, non-TB mycobacteria; TB, tuberculosis; VL, plasma viral load.
We report the case of a patient presenting with disseminated infection due to Mycobacterium genavense, a rare and hardly cultivable mycobacterial species. The patient benefited from direct sequencing of the bacterial rpoB gene from smear-positive clinical samples.
Case Report
Here, we describe the case of a 43-year-old woman, hospitalized for bicytopenia, in the presence of an inflamed supraclavicular lymph node.
The patient was diagnosed with human immunodeficiency virus-1 (HIV-1) infection nine years previously and had been treated with antiretroviral therapy (ART) containing abacavir/lamivudine and nevirapine for the past six years. She was then lost to follow up for three years and ART was interrupted.
The patient was admitted for Pneumocystis jiroveci pneumonia. Her CD4 cell count was 4 ml 21 with a plasma viral load (VL) of 273.423 copies ml
21
. Antiretroviral therapy containing tenofovir/emtricitabine and dolutegravir was begun.
Two months later, she was readmitted for fever, chills and night sweats. Clinical examination revealed an inflamed supraclavicular lymphadenopathy. The CD4 cell count was 66 cells ml 21 , and VL was 144 copies ml
. Further blood tests revealed anaemia (Hb: 10.8 g l
) a low white blood cell count (3030 leukocytes ml 21 ) and C-reactive Protein at 56 mg l 21 (Nl value: v5 mg l
).
A bone marrow aspirate was performed to exclude a haematological neoplasm. Cytological examination showed more than 60 % reactive plasmocytes locally, rare epithelioid granulomas and a single Langhans giant cell with no clear cell border (Fig. 1 ).
An 18F-fluorodeoxyglucose positron emission tomographycomputed tomography scan (FDG PET-CT scan) was performed and showed abnormal metabolic activity in the spleen, and in multiple lymph nodes located in the cervical, mediastinal, hepatic, periaortic and iliac regions (Fig. 2) .
A biopsy of the supraclavicular lymph node was performed. Direct smears showed over 100 acidfast bacilli per microscopic field, as illustrated in Fig. 3 . A TB-specific PCR (GeneXpert MTB/RIF, Cepheid) performed on the same day gave a negative result for the Mtb complex.
Despite these early microbiological results, anti-TB treatment composed of rifabutin (300 mg day 21 ), isoniazid (300 mg day 21 ), ethambutol (800 mg day
) and pyrazinamide (1000 mg day 21 ) began rapidly. Rifabutin was preferred to rifampicin to avoid drug-drug interactions with dolutegravir (Miller et al., 2015) . Five days later, the patient developed a biological hepatitis with liver enzymes five times over the upper normal limit. Pyrazinamide and isoniazid were stopped and liver function improved rapidly.
In the meantime, additional bacteriological investigations were performed. DNA was extracted from the lymph node using a commercial Fluorolyse kit (Hain Lifescience). The DNA strip assay, GenoType Mycobacterium CM (Hain Lifescience), confirmed the presence of the genus Mycobacterium, but did not provide a species identification. We performed DNA sequencing of the rpoB gene as described below. 
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As a first step, PCR amplification of the rpoB gene was carried out using the KOD Hot start master mix (Merck Millipore) with the primers, My9 and MycoR. These primers amplify a 800 bp region, presenting significant variations between mycobacterial species. Amplicons were purified with a QIAquick PCR purification kit (Qiagen) and diluted to 10 ng ml (Table 1) .
A sequence of 643 bp was obtained, for which analysis was performed using a Smartgene Bacteria module (Smartgene), which had 100 % homology with Mycobacterium genavense (accession number HM022216).
This technique was applied to fresh samples and to samples which had been fixed in paraffin.
Based on these results, clarithromycin (500 mg b.i.d.) was added rapidly to the treatment as recommended in the ATS/IDSA guidelines (Griffith et al., 2007) with good clinical evolution after one month.
Bone marrow and lymph node samples were cultured in an MGIT 960 instrument at 37 uC for ten weeks and in Lowenstein-Jenssen media incubated at 30 uC, 35 uC and 42 uC for eight weeks. All these media remained sterile.
Discussion
Immune reconstitution inflammatory syndrome (IRIS) is a common complication of ART initiation among HIV patients, particularly in those with an advanced state of immunosuppression (CD4 count v50 ml
21
). It typically occurs as CD4 cell numbers increase and it is linked to the paradoxical worsening of pre-existing subclinical opportunistic infections due to pathogens such as TB and NTM, Cryptococci and Cytomegalovirus (Barber et al., 2014; DeSimone et al., 2000; French, 2012; Griffith et al., 2007; Walker et al., 2015,) . IRIS can be severe and require the rapid initiation of an effective treatment.
Although Mtb remains the most prevalent species, in our particular experience (low incidence of TB), NTM represent an emerging problem (up to 50 % of Mycobacteria identified in the lab are non-TB species). NTM can be particularly severe among immunosuppressed patients, requiring a rapid diagnosis and rapid initiation of treatment (Murthy et al., 2015; van der Werf et al., 2014) . In the clinical case presented above, rapid identification of a species of NTM directly from a clinical sample permitted the definite exclusion of Mtb infection and the initiation of a treatment oriented towards Mycobacterium genavense.
Mycobacterium genavense is a clinically relevant pathogen among immunocompromised patients, causing disseminated disease with serious morbidity and mortality (Santos et al., 2014) . The prevalence of these infections may be underestimated due to the difficulties in recovering the bacteria from the usual culture media, such as MGIT and LJ, used in clinical practice (Thomsen et al., 1999) . Reports suggest that Mycobacterium genavense may grow on these media after up to 90 days of incubation at 45 uC in liquid media with an acid pH and Mycobactin J as a supplement. These specific requirements are not implementable in routine practice.
Rapid and accurate diagnostic methods for this growing group of opportunistic pathogens should, therefore, be made widely accessible. Using the technique described above, we were able to perform rapid species identification directly from smear-positive clinical specimens. This technique has since been implemented in our routine workflow for smear-positive samples with negative Mtb PCR. 
